Nov 19 (Reuters) - The U.S. Food and Drug Administration on Thursday approved emergency use of Eli Lilly and Co’s antibody drug baricitinib, in combination with remdesivir, to treat COVID-19 patients.
The drug was authorized for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring oxygen support. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)
Our Standards: The Thomson Reuters Trust Principles.